Novel Coronavirus SARS-CoV-2
i
Credit: National Institute of Allergy and Infectious Diseases-Rocky Mountain Laboratories, NIH
In response to the unprecedented threat caused by the COVID-19 outbreak, IDDO is working with key stakeholders to identify how our expertise can be used optimally. Our technical and personnel resources are mobilised to address the knowledge gaps and improve outcomes for people affected by the novel coronavirus.
Our work on COVID-19

We are working on a living systematic review, and a searchable, interactive visualisation of the results database is being created.

We are part of a global group of scientists, physicians, funders and policy makers from over 70 institutions in more than 30 countries who have launched a Clinical Research Coalition to respond to COVID-19 in resource-poor settings.

ISARIC Clinical Data Platform

IDDO and ISARIC are partners in a global collaboration that collects and shares COVID-19 clinical data to maximise research that informs clinical practice and public health response.

 

Medicine Quality and COVID-19

IDDO’s Medicine Quality Research Group has developed a system for collating and curating global data on the quality of essential medical products and occurrence of substandard and falsified (SF) medical products in the lay press – the MQM Globe.

 

Explore COVID-19 clinical trials around the world in an open-access, cloud-based knowledge graph. The visualisation is based on IDDO’s living systematic review. 

 

Explore our COVID-19 publications

News